TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Biopharma AS
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
17,808
|
16,119
|
18,824 |
| Financial expenses |
16
|
0
|
0 |
| Earnings before taxes |
3,855
|
2,486
|
617 |
| Total assets |
11,349
|
7,458
|
11,510 |
| Current assets |
11,349
|
7,458
|
11,510 |
| Current liabilities |
7,112
|
3,031
|
8,667 |
| Equity capital |
3,685
|
3,701
|
1,878 |
| - share capital |
19
|
20
|
21 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
32.5%
|
49.6%
|
16.3% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
21.6%
|
15.4%
|
3.3% |
| Return on assets (ROA) |
34.1%
|
33.3%
|
5.4% |
| Current ratio |
159.6%
|
246.1%
|
132.8% |
| Return on equity (ROE) |
104.6%
|
67.2%
|
32.9% |
| Change turnover |
2,498
|
-1,548
|
364 |
| Change turnover % |
16%
|
-9%
|
2% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.